Background. Two large, prospective studies (12-03; OSAKA) compared the efficacy and tolerability of prolonged-release versus immediate-release tacrolimus in kidney transplant patients also receiving mycophenolate mofetil and low-dose corticosteroids (without induction therapy). Methods. Data were combined into one database to compare results over 24 weeks using 3 alternative endpoints: biopsy-confirmed acute rejection (BCAR); the Food and Drug Administration composite endpoint (graft loss, BCAR, and loss to follow-up), and the European Medicines Agency composite endpoint (graft loss, BCAR, and graft dysfunction). The 95% confidence intervals were calculated (10% noninferiority margin). Results. Overall, 633 patients received prolonged-release tacrolimus (12-03, n ¼ 331; OSAKA, n ¼ 302) and 645 received immediate-release tacrolimus (n ¼ 336; n ¼ 309). Baseline characteristics were comparable. Proportionately more patients receiving prolonged-release tacrolimus had trough levels of 5e15 ng/mL on day 1 (60.8%) and 2 (56.6%) versus immediate-release tacrolimus (42.5% and 43.9%, respectively, both P < .001). Efficacy of prolonged-release and immediate-release tacrolimus were similar as assessed by BCAR (13.9% vs 14.1%, respectively), European Medicines Agency composite endpoint (40.3% vs 38.3%) and US Food and Drug Administration composite endpoint (21.5% vs 19.8%).
Conclusions. Novel efficacy endpoints as required by the European Medicines Agency and US Food and Drug Administration demonstrate noninferiority of prolonged-release versus immediate-release tacrolimus. Significantly more patients treated with prolongedrelease tacrolimus versus immediate-release tacrolimus achieved trough levels of 5 to 15 ng/mL early after transplantation. ClinicalTrials.gov NCT00189839; NCT00717470. D ESPITE improvements in short-term graft survival after kidney transplantation, long-term graft and patient outcomes have not shown similar improvements [1, 2] . Improving long-term outcomes therefore remains a major challenge facing clinicians today [3] .
Ensuring appropriate exposure to immunosuppressive therapy posttransplantation plays a crucial role in improving long-term outcomes, particularly in the immediate posttransplant period, as increased intrapatient variability in exposure is associated with poorer outcomes [4e10] . The once-daily, prolonged-release formulation of tacrolimus was developed to provide more consistent exposure, reduce intrapatient variability, and improve adherence [11e13] . Data for this formulation have demonstrated comparable steady-state exposure to the twice-daily, immediate-release formulation in de novo kidney transplant recipients [14, 15] , and showed significantly lower intrapatient variability in tacrolimus trough concentrations in stable kidney transplant recipients converted from immediate-release tacrolimus [11, 12, 16] . However, variability in exposure for prolonged-release versus immediate-release tacrolimus has not previously been compared in de novo kidney transplant recipients. Although achieving potential long-term benefits is the ultimate goal for prolonged-release tacrolimus, it is first necessary to demonstrate that the short-term efficacy of the prolongedrelease formulation is comparable with that of the immediate-release tacrolimus formulation.
Two large prospective studies comparing prolongedrelease tacrolimus with immediate-release tacrolimus have been performed in de novo kidney transplantation. The first (Study 12-03) was a randomized, double-blind, placebocontrolled study over 24 weeks followed by an open-label extension of 12 months [17] ; the second trial, OSAKA (Optimising immunoSuppression After Kidney transplantation with Advagraf), was a 24-week, open-label, parallel-arm study [18] . Both studies assessed the noninferiority of prolonged-release tacrolimus and immediate-release tacrolimus when used in combination with mycophenolate mofetil (MMF) and low-dose corticosteroids. The primary endpoints differed between the 2 trials. In Study 12-03, the primary endpoint was the incidence of biopsy-confirmed acute rejection (BCAR) based on local diagnosis over 24 weeks of treatment [17] . The OSAKA study used a composite endpoint of graft loss, BCAR, and graft dysfunction, estimated using glomerular filtration rate (eGFR) calculated by the Modification of Diet in Renal Disease-4 formula of <40 mL/min/1.73 m 2 at the end-of-study visit, based on the European Medicines Agency (EMA) guidelines [18, 19] . Using a measure of graft function, as recommended by the EMA, provides a comprehensive assessment of treatment efficacy [20] , but this endpoint has not been used routinely in clinical trials to date. It also differs from the advice provided by the US Food and Drug Administration (FDA), which recommends a composite endpoint comprising graft loss, BCAR, and loss to follow-up.
In this analysis, we used 24-week follow-up data from the 2 tacrolimus studies (12-03 and OSAKA) combined into a single database to create a large patient population to evaluate the effects of prolonged-release tacrolimus and immediate-release tacrolimus formulations using different efficacy parameters (including the EMA and FDA composite endpoints). This study is the first to compare variability in exposure with prolonged-release versus immediate-release tacrolimus in de novo kidney transplant recipients. Early tacrolimus exposure, outcomes by donor type, and tolerability were also evaluated for the 2 tacrolimus formulations.
MATERIALS AND METHODS
This analysis used data from the 12-03 (NCT00189839) and OSAKA studies (NCT00717470), combined into a single database, to compare outcomes with prolonged-release tacrolimus (Advagraf, Astellas Pharma Europe BV, Leiden, the Netherlands, hereafter termed prolonged-release tacrolimus) and immediate-release tacrolimus (Prograf, Astellas Pharma Ltd, Chertsey, UK, hereafter termed immediate-release tacrolimus) in de novo kidney transplantation.
Both studies enrolled adult patients with end-stage renal disease receiving a kidney transplant from deceased or living donors with compatible ABO blood types. Study 12-03 compared prolongedrelease tacrolimus and immediate-release tacrolimus at an initial postoperative dose of 0.2 mg/kg per day, in combination with lowdose MMF and corticosteroids, in a randomized, double-blind, placebo-controlled trial [17] . OSAKA compared 4 tacrolimusbased arms in a randomized, open-label study; only the patients who received immediate-release tacrolimus or prolonged-release tacrolimus at an initial dose of 0.2 mg/kg per day, in combination with low-dose MMF and corticosteroids (arms 1 and 2), were included in this analysis [18] . Patients in the other arms of the OSAKA study were excluded because they received prolongedrelease tacrolimus either at a higher starting dose (0.3 mg/kg per day) or in combination with basiliximab in a steroid-avoidance regimen.
Both studies were conducted in accordance with the Declaration of Helsinki, Good Clinical Practice, and the International Conference on Harmonisation guidelines [21e23] . Both studies were approved by the Independent Ethics Committee or Institutional Review Board at each study site. Written informed consent was obtained from all patients before enrollment.
Procedures
In both studies, patients received a preoperative oral tacrolimus dose of 0.1 mg/kg, administered as prolonged-release tacrolimus or immediate-release tacrolimus. After transplantation (day 0), tacrolimus was initiated at 0.2 mg/kg per day for both formulations; doses were then adjusted to maintain recommended tacrolimus whole blood trough levels: 10 to 15 ng/mL (days 1e28) and 5 to 15 ng/mL (days 29e168) for Study 12-03; and 10 to 15 ng/mL (days 1e14), 5 to 12 ng/mL (days 15e42), and 5 to 10 ng/mL (days 43e168) for OSAKA. Immediate-release tacrolimus was taken in the morning and evening, whereas prolonged-release tacrolimus was taken in the morning only. Patients in Study 12-03 also received matching placebo for prolonged-release tacrolimus or immediaterelease tacrolimus, as appropriate, to maintain study blinding.
MMF was administered preoperatively (1 g), then at 1 g twice-daily for days 1-14, and at 500 mg twice-daily thereafter in both studies. No induction therapy was administered. Methylprednisolone (or the equivalent) was administered as an intravenous bolus dose of up to 1000 mg (Study 12-03) or up to 500 mg (OSAKA) perioperatively, and of 125 mg on day 1 (both studies). Oral prednisolone (or equivalent) was started at 20 mg/d on days 2 to 14 and tapered as follows in both studies: 15 mg/d (days 15e28), 10 mg/d (days 29e42), 5 mg/d (days 43e84), and 0e5 mg/d (thereafter).
Assessments
In both Study 12-03 and OSAKA, BCAR (based on local pathology following Banff 97 criteria) [24] , renal function [25] , graft and patient survival were evaluated at the end-of-study follow-up or last visit [17, 18] . In Study 12-03, the primary endpoint was incidence of BCAR within 24 weeks after transplantation; renal function was determined using creatinine clearance (CockcrofteGault) and the eGFR was calculated using the Modification of Diet in Renal Disease-4 formula as a post hoc analysis [17] . In OSAKA, the primary efficacy variable was the incidence of efficacy failure (based on the EMA composite endpoint) [18] , defined as incidence and time to first occurrence of graft loss (retransplantation, nephrectomy, death, or dialysis at study end or at time of discontinuation, unless superseded by follow-up information that indicated graft survival), BCAR, or graft dysfunction (defined as eGFR [Modification of Diet in Renal Disease-4] of <40 mL/min/1.73m 2 ) at day 168. In this combined analysis, data collected up to the formal end-ofstudy visit or the follow-up visit were used to evaluate 3 different efficacy endpoints. These were (a) the single endpoint of BCAR, (b) the FDA composite endpoint of graft loss, BCAR, or loss to followup, and (c) the EMA composite endpoint. In addition, the mean tacrolimus dose and mean tacrolimus whole blood levels were assessed over the first 7 days posttransplantation and throughout the study at predefined time points. The intrapatient variability of tacrolimus exposure of both formulations was assessed over the 24-week study period. The incidence of delayed graft function was defined as dialysis for >1 day within the first 7 days posttransplantation. Tolerability profiles for both tacrolimus formulations were also assessed.
Statistical Analysis
Data from the full-analysis set (FAS) for each study (all randomized patients who had a transplant and received !1 dose of tacrolimus) were combined into a single database. The analyses for this study were performed using the FAS population to provide the most conservative analysis of the data. Noninferiority was demonstrated if the lower limit of the 95% confidence interval for the difference in efficacy failure rate was above À10% for the combined prolonged-release tacrolimus arm versus the immediate-release tacrolimus arm. Although this pooled analysis was retrospective, a noninferiority margin of 10% was deemed appropriate, because this margin was the narrower (and most difficult to meet) of the two noninferiority margins for the two studies. In OSAKA, the predefined noninferiority margin was 12.5%, whereas in Study 12-03 the margin was 10%. Tacrolimus dose and exposure were calculated using the FAS and compared using a t test. The intrapatient variability of tacrolimus exposure was expressed as the coefficient of variation for study completers (completer analysis). In addition, probabilities for event-free survival for the EMA and FDA composite endpoints (KaplaneMeier method) were calculated and the homogeneity of both arms was assessed by the log-rank test. P <.05 was considered statistically significant. Laboratory parameters were compared using an unpaired t test.
RESULTS

Patient and Donor Characteristics
A total of 1278 patients, who received a starting dose of 0.2 mg/kg per day of tacrolimus, were included in the combined analysis database (FAS). Of these, 633 patients received prolonged-release tacrolimus (12-03, n ¼ 331; OSAKA, n ¼ 302) and 645 received immediate-release tacrolimus (12-03, n ¼ 336; OSAKA, n ¼ 309). In total, 1061 patients were study completers; 508 patients (80.3%) in the prolonged-release tacrolimus arm and 553 (85.7%) in the immediate-release tacrolimus arm. The reasons for study discontinuation are reported in Fig 1. Demographics and baseline characteristics were generally well balanced between the treatment arms ( Table 1 ). The majority of organs were from deceased donors (80.0% overall) and donors <60 years old (77.7%); more than onehalf of donors were male (56.7%).
Tacrolimus Dosing and Exposure
The mean daily doses of tacrolimus were similar on day 1 but significantly higher throughout the study in the arm receiving prolonged-release tacrolimus versus immediaterelease tacrolimus (Table 2) . However, the mean AE standard deviation tacrolimus trough levels were generally significantly lower with prolonged-release tacrolimus versus immediate-release tacrolimus throughout the study ( Table 2 ). The proportion of patients with tacrolimus trough levels of 5 to 15 ng/mL was higher with prolonged-release tacrolimus compared with immediate-release tacrolimus in the first 2 days post-transplantation (P <.001); however, this was comparable between arms by day 3 (Fig 2) . The proportion of patients with tacrolimus blood trough levels of >20 ng/mL was significantly lower in patients treated with prolonged-release tacrolimus compared with immediaterelease tacrolimus in the first 2 days post-transplantation (Fig 2) . In the completer analysis, prolonged-release tacrolimus demonstrated significantly less intrapatient variability of exposure compared with immediate-release tacrolimus by day 168 (coefficient of variation, 0.372 vs 0.398; P ¼ .015). When the data were dose-normalized by milligram, a similar pattern was observed (0.380 vs 0.411; P ¼ .016); however, no difference was observed when data were dose-normalized by milligrams per day (0.384 vs 0.397; P ¼ .286).
Concomitant Medication
As per the study design, no antibody induction therapy was administered in either treatment arm and all patients received low-dose MMF and corticosteroids throughout the study. The median doses of MMF and corticosteroids at day 168 were 1 g and 5 mg, respectively, in both arms. More than 90% of patients received maintenance steroids throughout the study.
Efficacy Endpoints
For all 3 endpoints, the difference in response with prolonged-release tacrolimus and immediate-release tacrolimus ranged from À0.2% to þ2.0%, and 95% confidence intervals were between À4.0% and þ7.4%. These data are within the 10% margin, which demonstrates noninferiority of prolonged-release tacrolimus versus immediate-release tacrolimus ( Table 3 ).
The incidence of BCAR was similar with prolongedrelease tacrolimus (13.9%) and immediate-release tacrolimus (14.1%). The FDA composite endpoint was reached by 21.5% versus 19.8% of patients, respectively ( Fig 3A) ; with both treatments, BCAR was the main reason for efficacy failure, with very few patients lost to follow-up (Table 3) . The EMA composite endpoint was reached by 40.3% of patients treated with prolonged-release tacrolimus and 38.3% of those receiving immediate-release tacrolimus ( Fig  3B) ; with both treatments, graft dysfunction was the dominant reason for efficacy failure (Table 3) . Renal function was similar for both treatment arms at day 168 (prolongedrelease tacrolimus: 47.3 mL/min per 1.73 m 2 ; immediaterelease tacrolimus: 49.5 mL/min per 1.73 m 2 ). Stratification of the patients according to deceased or living organ donors showed no significant differences in efficacy between the 2 treatments. For patients receiving organs from deceased donors, the incidence of BCAR was 12.0% (61/510) for prolonged-release tacrolimus and 12.5% (64/512) for immediate-release tacrolimus, and the incidence of patients who achieved the EMA and FDA composite endpoints was 40.3% (255/633) and 21.5% (136/633), respectively, for prolonged-release tacrolimus and 38.3% (247/645) and 19.8% (128/645) for immediate-release tacrolimus. For living donor transplants, the incidence of BCAR was 22.0% (27/123) and 18.9% (27/143) with prolonged-release tacrolimus and immediate-release tacrolimus, respectively. For the composite efficacy endpoints, the incidence was 35 
Tolerability Profile
Prolonged-release and immediate-release tacrolimus had similar adverse event profiles over the study period. The most common adverse events are presented in Table 4 . The incidence of new-onset diabetes mellitus (World Health Organization/American Diabetes Association criteria) was low throughout the study (13.4% of patients with prolonged-release tacrolimus compared with 16.4% with immediate-release tacrolimus; P ¼ .157). Ongoing antidiabetic medication and ongoing insulin medication were required by 11.9% and 6.9%, respectively, of patients treated with prolonged-release tacrolimus, and 13.1% and 7.9%, respectively, of those treated with immediate-release tacrolimus (P ¼ .587 and P ¼ .570, respectively). The mean AE standard deviation serum total cholesterol levels showed slight and similar increases over the study period with prolonged-release tacrolimus and immediate-release tacrolimus. The mean AE standard deviation triglyceride levels decreased over the 24-week period in both arms; the lowdensity lipoprotein/high-density lipoprotein cholesterol ratio was similar with both treatments.
DISCUSSION
This combined analysis showed that prolonged-release tacrolimus was noninferior to immediate-release tacrolimus at 24 weeks of follow-up in patients undergoing de novo kidney transplantation, regardless of the efficacy endpoint used. To our knowledge, this is the first study to compare the EMA-and the FDA-recommended composite efficacy endpoints in kidney transplantation on such a large scale. By including graft function within the EMA composite endpoint, these results can be considered a comprehensive evaluation of treatment efficacy. Results from this large population of patients demonstrated that the prolongedrelease formulation provided a narrower range of tacrolimus exposure versus the immediate-release formulation over the initial 2 days after transplantation, with reduced variability maintained over the follow-up period. This study was the first to compare the variability in exposure for prolonged-release versus immediate-release tacrolimus in de novo kidney transplant recipients.
Tacrolimus is known to have a narrow therapeutic index, with both overexposure and underexposure having potentially important effects on clinical outcomes [26] . In this study, a higher proportion of patients achieved tacrolimus trough levels of 5 to 15 ng/mL with prolonged-release tacrolimus versus immediate-release tacrolimus during the first 2 days posttransplantation. A lower initial tacrolimus exposure reported with prolonged-release tacrolimus compared with the immediate-release formulation has also been reported previously [15, 27, 28] . After the same initial dose, adjustments to obtain target levels resulted in significantly lower mean doses of immediate-release versus prolonged-release tacrolimus (w 17% from days 84-168). Significantly fewer patients receiving prolonged-release tacrolimus experienced potentially toxic overexposure (trough levels of >20 ng/mL) in the early days after transplantation compared with those receiving immediaterelease tacrolimus. It is important to note, however, that the initial tacrolimus dose (0.2 mg/kg per day) used in the studies included in this analysis was higher than the initial tacrolimus dose generally used in clinical practice today. A lower initial dose of prolonged-release tacrolimus may result in fewer patients reaching trough levels of >20 ng/mL.
Low variability of tacrolimus exposure may be important to prevent patients' trough levels falling outside the therapeutic range, because it is becoming increasingly welldocumented that high intrapatient variability in tacrolimus exposure is associated with poorer outcomes after transplantation [5e8,29e31]. In a single-center study of 297 kidney transplant recipients, high intrapatient variability in tacrolimus clearance was a significant predictor of long-term graft failure [7] . Similarly, a study of more than 300 adult Data are mean (standard deviation). *P values were calculated using a t test. kidney transplant recipients demonstrated that patients with high variability in tacrolimus trough levels had increased 1-year acute rejection and lower graft survival than those with lower variability [32] . Intrapatient variability in tacrolimus trough levels has also been found to predict graft loss and donor-specific antibody development in patients after kidney transplantation [8, 31] . Interestingly, stable kidney transplant recipients who converted from immediate-release tacrolimus to prolonged-release tacrolimus showed significantly lower intrapatient variability in tacrolimus trough concentrations [11, 12, 16] . Data from our analysis demonstrated that intrapatient variability was significantly lower in the patients receiving prolonged-release tacrolimus versus immediate-release tacrolimus over 168 days posttransplantation. However, no difference was observed when the data were dose normalized by milligrams per day. It is also important to note that the difference in variability between the 2 tacrolimus formulations was only observed for the completer analysis and that variability in tacrolimus exposure in the early posttransplant period remains difficult to measure accurately owing to changes in tacrolimus dose. Prolonged-release tacrolimus was noninferior to immediate-release tacrolimus for all 3 measures of efficacy used in this analysis, though the level of efficacy reported varied with the definition. In our analysis, efficacy failure rate was highest for the EMA versus FDA composite endpoint (the proportion of patients reaching the EMA composite endpoint was approximately double that of the FDA endpoint at day 168). Graft dysfunction was the main driver of failure for the EMA composite endpoint; however, the proportion of patients experiencing graft dysfunction was comparable between treatments (31.4% prolongedrelease tacrolimus; 30.7% immediate-release tacrolimus), . ‡ Includes all deaths throughout the study and up to 6 months of follow-up. § Graft loss was defined as retransplantation, nephrectomy, death, or dialysis at end or at time of discontinuation, unless superseded by follow-up information that indicated graft survival.
and mean eGFR at day 168 was similar with both formulations. In a previous study in de novo kidney transplant patients, renal function parameters were also similar with prolonged-release tacrolimus versus immediate-release tacrolimus over 12 months of follow-up [33] . In a singlecenter observational study by Tinti et al [27] , a significant improvement in eGFR over 6 months was reported after conversion from immediate-release tacrolimus to prolonged-release tacrolimus, whereas van Hooff et al [34] and Guirado et al [28] demonstrated stable renal function for up to 4 years in kidney transplant patients who had received de novo prolonged-release tacrolimus, and also in those who had been converted from the immediate-release to the prolonged-release formulation.
A previous randomized, controlled study in de novo kidney transplant recipients used the FDA composite endpoint and showed a similar efficacy failure rate with prolonged-release tacrolimus and immediate-release tacrolimus (14.0% vs 15.1%, respectively) at 1 year posttransplantation [33] . The lower rates compared with the current analysis probably reflect differences in the organdonor population; approximately 50% of organs were from deceased donors compared with 80% in the current analysis. However, perhaps the most important factor was the use of antibody induction by Silva et al [33] versus no antibody induction in the current analysis.
Comparable tolerability profiles were observed with prolonged-release tacrolimus and immediate-release tacrolimus, consistent with findings from previous studies in kidney and liver transplant settings [33,35e37] . The incidence of new-onset diabetes mellitus was slightly, but not significantly, lower with prolonged-release versus immediate-release tacrolimus, with correspondingly lower antidiabetic medication and insulin use in the prolongedrelease tacrolimus arm, although again this difference was not significant.
The characteristics of the populations involved in the 2 studies were largely similar, hence their suitability for combining into a single database. There were only minor differences in treatment regimens between the 0.2 mg/kg per day arms in Study 12-03 and OSAKA. Although the target whole blood trough ranges were narrower in OSAKA than Study 12-03, the same target trough range over the first 14 days post-transplantation (10e15 ng/mL) allowed early exposure to be compared between the 2 formulations in this combined analysis. However, there are limitations to this study, including those reported for the individual studies [17, 18] . In Study 12-03, both treatment arms showed equally well-maintained renal function at 12 months; however, only 24-week data have been published for the OSAKA study. More patients in the immediate-release tacrolimus arm of the OSAKA study experienced BCAR than did those in the prolonged-release tacrolimus arm, whereas it was the opposite in Study 12-03. It is possible that these differences could be due to the optimization of the overall immunosuppressive regimen with prolonged-release tacrolimus over the time between the two studies, because Study 12-03 was concluded a year and a half before enrollment into the OSAKA study.
CONCLUSIONS
This analysis from a combined database of two large, randomized trials enabled comparison of the treatments using three different efficacy measures (BCAR, and EMA and FDA composite endpoints) in kidney transplantation. Regardless of the measure used, prolonged-release tacrolimus was noninferior to immediate-release tacrolimus treatment in de novo kidney transplantation. The proportion of patients who achieved trough levels of 5 to 15 ng/mL was higher with prolonged-release tacrolimus compared with immediate-release tacrolimus early after transplantation, and tolerability profiles were comparable between the 2 formulations.
